Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

Launched by AGELESSRX · Oct 26, 2020

Keywords

ClinConnect Summary

The researchers will treat 40 patients with metformin (1500 mg/day) and LDN (4.5 mg/day) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19. These 40 patients will be compared with 40 control patients who will receive regular care. All patients will be asked to complete surveys at baseline and after 1, 2, and 4 weeks after initiation of treatment. The difference with baseline at each time point will be assessed. The surveys will assess COVID-19 symptoms severity.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 30-70
• • Any sex
• • Any ethnicity
• • Adequate cognitive function to be able to give informed consent
• • Technologically competent to complete web forms and perform video calls with the PI
• • Positive PCR (polymerase chain reaction) test result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) within the last 10 days
• • At least two COVID-19 symptoms as assessed by laboratory or patient self-reporting started within the last 3 days
• • Willing to fill out regular questionnaires
• • Willing to take metformin and LDN
• Exclusion Criteria:
• • Clinically significant hepatic, renal, or cardiac impairment (as determined by previous clinical judgement)
• • Hypoglycemia
• • Currently on drugs for COVID-19
• • Hospitalization for COVID-19
• • (Suspected) pregnancy or breastfeeding
• • Active cancer
• • Uncontrolled mental health issues
• • On any medication with major interactions with metformin or LDN
• • Taking opioid analgesics, or being treated for opioid addiction/recovery
• • Opioid dependence or withdrawal syndrome
• • Known sensitivity to metformin or naltrexone
• • Current users of metformin or naltrexone